IL105285A0 - Compositions for the treatment of diabetes - Google Patents

Compositions for the treatment of diabetes

Info

Publication number
IL105285A0
IL105285A0 IL105285A IL10528593A IL105285A0 IL 105285 A0 IL105285 A0 IL 105285A0 IL 105285 A IL105285 A IL 105285A IL 10528593 A IL10528593 A IL 10528593A IL 105285 A0 IL105285 A0 IL 105285A0
Authority
IL
Israel
Prior art keywords
diabetes
compositions
treatment
Prior art date
Application number
IL105285A
Other languages
English (en)
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of IL105285A0 publication Critical patent/IL105285A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL105285A 1992-04-06 1993-04-02 Compositions for the treatment of diabetes IL105285A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201076A SE9201076L (sv) 1992-04-06 1992-04-06 Användningen av gamla läkemedel för behandling av diabetes

Publications (1)

Publication Number Publication Date
IL105285A0 true IL105285A0 (en) 1993-08-18

Family

ID=20385863

Family Applications (1)

Application Number Title Priority Date Filing Date
IL105285A IL105285A0 (en) 1992-04-06 1993-04-02 Compositions for the treatment of diabetes

Country Status (16)

Country Link
US (1) US5594005A (hu)
EP (1) EP0634931A1 (hu)
JP (1) JPH07506568A (hu)
KR (1) KR950700738A (hu)
CN (1) CN1081671A (hu)
AU (1) AU667362B2 (hu)
CA (1) CA2131831C (hu)
EE (1) EE03090B1 (hu)
HU (1) HUT69710A (hu)
IL (1) IL105285A0 (hu)
NO (1) NO943723D0 (hu)
NZ (1) NZ251494A (hu)
PH (1) PH30820A (hu)
SE (1) SE9201076L (hu)
WO (1) WO1993019756A1 (hu)
ZA (1) ZA932450B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
FR2827600A1 (fr) * 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN102176906B (zh) * 2008-10-09 2014-07-02 新树株式会社 Panduratin衍生物或提琴形凹唇姜提取物的全新用途
MX2013004169A (es) 2010-10-14 2013-06-05 Immunahr Ab 1, 2-dihidro-4-hidroxi-2-oxo-quinolina-3-carboxanilidas como activadores del receptor de hidrocarburo aromatico.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1034124A (en) * 1973-05-11 1978-07-04 Ciba-Geigy Ag Process for the manufacture of new quinolines
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US5310913A (en) * 1989-06-09 1994-05-10 Kabi Pharmacia Aktiebolag Derivatives of quinoline-3-carboxanilide
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
SE9001111D0 (sv) * 1990-03-27 1990-03-27 Pharmacia Ab Supportive use

Also Published As

Publication number Publication date
SE9201076L (sv) 1993-10-07
HUT69710A (en) 1995-09-28
CN1081671A (zh) 1994-02-09
EE03090B1 (et) 1998-06-15
NZ251494A (en) 1997-07-27
KR950700738A (ko) 1995-02-20
JPH07506568A (ja) 1995-07-20
US5594005A (en) 1997-01-14
CA2131831C (en) 1999-03-09
NO943723L (no) 1994-10-05
PH30820A (en) 1997-10-17
EP0634931A1 (en) 1995-01-25
AU667362B2 (en) 1996-03-21
AU3913193A (en) 1993-11-08
SE9201076D0 (sv) 1992-04-06
ZA932450B (en) 1993-10-20
WO1993019756A1 (en) 1993-10-14
CA2131831A1 (en) 1993-10-14
HU9402854D0 (en) 1995-01-30
NO943723D0 (no) 1994-10-05

Similar Documents

Publication Publication Date Title
GB9208339D0 (en) Treatment composition
GB9215633D0 (en) Novel treatment
GB2264235B (en) Composition for nasal treatment
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
GB9211148D0 (en) Novel treatment
GB9225860D0 (en) Novel treatment
IL105285A0 (en) Compositions for the treatment of diabetes
GB9201920D0 (en) Novel treatment i
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
ZA929879B (en) Compositions for the treatment of mammalian diseases.
IL99666A0 (en) Pharmaceutical compositions for the treatment of diabetes
GB9217547D0 (en) Leather treatment compositions
IL105690A0 (en) Pharmaceutical compositions for the treatment of arrhythmia
IL104756A0 (en) Composition for the treatment of glaucoma
GB9203637D0 (en) Novel treatment
GB9323550D0 (en) Composition for the treatment of hydrothyroidism
EP0579077A3 (en) 1,3,4-thiadiazinones for the treatment of cardiovascular diseases
HU895550D0 (en) Compositions for the treatment of leishmaniasis
GB9022298D0 (en) Treatment composition
GB9225859D0 (en) Novel treatment
IL119421A0 (en) Pharmaceutical compositions for the treatment of arrhythmia
GB9522247D0 (en) Composition for the treatment of gastra-duodenal ulcers
IL106961A0 (en) Pharmaceutical compositions for treatment of the eyes
IL106917A0 (en) Compositions for the treatment of skin disorders
GB9104920D0 (en) Therapeutical composition for the treatment of multiple sclerosis